Events

Safety Alert for TRUCAL HbA1c Liquid, Presentation: X 0.25 mL - Level 1: 1 X 0.25 mL / Level 2: 1 X 0.25 mL / Level 3: 1 X 0.25 mL / Level 4: 1 X 0.25 mL, Registration No. 10350840198, lots: 19433-19436, 19949-19952

According to Agência Nacional de Vigilância Sanitária (ANVISA), this safety alert involved a device in Brazil that was produced by Biosys Ltda; DiaSys Diagnostic Systems Gmbh.

What is this?

Alerts provide important information and recommendations about products. Even though an alert has been issued, it does not necessarily mean a product is considered to be unsafe. Safety Alerts, addressed to health workers and users, may include recalls. They can be written by manufacturers, but also by health officials.

Learn more about the data here
  • Type of Event
    Safety alert
  • Event ID
    1494
  • Date
    2014-12-26
  • Event Country
    Brazil
  • Event Source
    ANVISA
  • Event Source URL
    http://www.anvisa.gov.br/sistec/alerta/consultaralerta.asp
  • Notes / Alerts
    Brazilian data is current through June 2018. All of the data comes from Anvisa, except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of data from the U.S. and Brazil.
  • Extra notes in the data
    According to the company's manifestation, since HbA1c is used as a monitoring parameter that takes into account the history of glycemia, a critical impact is not expected in the decision of the therapy, since it will be established taking into consideration other parameters current clinical practice.
  • Reason
    Internal measurements performed by the manufacturer of the product showed that the values ​​obtained with the onhba1c kit (2/3 regent system) calibrated with the cited trucal hba1c batches presented lower values ​​when compared with measurements performed with the hplc comparison system. the manufacturer assumes that the reagent reacts differently when using fresh sample or frozen sample, and the ifcc reference material used for reagent standardization was frozen sample. because of these observations, patient sample values ​​around the endpoints (48mmol / mol as diagnostic cut-off and 53 mmol / mol as therapy target value) are 6-10% lower.
  • Action
    The manufacturer company DiaSys repatriated the reagent using fresh sample as reference material, which was standardized with the HPLC method calibrated by the IFCC material. The registry holder in Brazil forwarded communication on the new standardization and also directed the laboratories to check the need to check the values ​​of patients previously determined

Device

TRUCAL HbA1c Liquid, Presentation: X 0.25 mL - Level 1: 1 X 0.25 mL / Level 2: 1 X 0.25 mL / Leve...

Manufacturer

Biosys Ltda; DiaSys Diagnostic Systems Gmbh
  • Source
    ANVSANVISA